Microbot rises on application to start human trials with robotic surgical system
05/02/2024 13:23
** Shares of medical device manufacturer Microbot Medical
MBOT.O rise ~1.7% to $1.23 premarket
** Co says it has submitted an Investigational Device
Exemption (IDE) application to the U.S. FDA for the company to
commence human trials with its LIBERTY Robotic Surgical System
** IDE allows an investigational device to be used in a
clinical study to collect safety and effectiveness data
** In October, co said its Robotic Surgical System performed
with 100% usability and technical success without any adverse
events in a pre-clinical study testing the system in animals
** Up to last close, stock down 61.8% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Microbot Medical
See all newsBrief: Microbot Medical® Enters Into An Agreement To Expand Access For America’S Veteran And Military Patient Populations
Microbot Medical rises as U.S. federal supply deal expands reach of robotic surgical device
Brief: Microbot Medical Recorded Revenue During Its Quarter Ended March 31, Benefiting From Limited Market Release Of Liberty System
Brief: Microbot Medical®’S Liberty® Endovascular Robotic System Is Now Adopted By Multiple Accounts Across Key Territories Including Two Access-Pvi Pivotal Clinical Trial Sites
Brief: Microbot Medical Continues Its 2025 Momentum Announces Key 2026 Milestones